First Foundation Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.07M Sell
9,520
-310
-3% -$68.8K 0.08% 140
2025
Q4
$2.25M Buy
9,830
+34
+0.3% +$7.75K 0.08% 133
2025
Q3
$2.27M Sell
9,796
-77
-0.8% -$15.7K 0.08% 137
2025
Q2
$1.83M Buy
9,873
+1,632
+20% +$303K 0.07% 144
2025
Q1
$1.73M Sell
8,241
-671
-8% -$130K 0.07% 136
2024
Q4
$1.58M Buy
8,912
+13
+0.1% +$2.39K 0.06% 142
2024
Q3
$1.76M Sell
8,899
-811
-8% -$151K 0.07% 134
2024
Q2
$1.67M Sell
9,710
-156
-2% -$25.8K 0.06% 130
2024
Q1
$1.8M Buy
9,866
+760
+8% +$131K 0.07% 126
2023
Q4
$1.41M Sell
9,106
-5,952
-40% -$868K 0.06% 145
2023
Q3
$2.24M Buy
15,058
+1,089
+8% +$160K 0.1% 119
2023
Q2
$1.88M Buy
13,969
+943
+7% +$138K 0.08% 133
2023
Q1
$2.08M Buy
13,026
+1,360
+12% +$208K 0.1% 126
2022
Q4
$1.89M Sell
11,666
-138
-1% -$21.2K 0.09% 126
2022
Q3
$1.58M Buy
11,804
+206
+2% +$29.6K 0.08% 137
2022
Q2
$1.78M Sell
11,598
-1,708
-13% -$261K 0.08% 129
2022
Q1
$2.16M Buy
13,306
+1,323
+11% +$192K 0.08% 127
2021
Q4
$1.62M Buy
11,983
+376
+3% +$44.4K 0.06% 162
2021
Q3
$1.25M Buy
11,607
+513
+5% +$58.6K 0.05% 177
2021
Q2
$1.25M Buy
11,094
+1,268
+13% +$143K 0.05% 191
2021
Q1
$1.06M Sell
9,826
-740
-7% -$79.2K 0.05% 193
2020
Q4
$1.13M Buy
10,566
+269
+3% +$25.9K 0.05% 177
2020
Q3
$902K Sell
10,297
-244
-2% -$23K 0.04% 189
2020
Q2
$1.03M Buy
10,541
+2,838
+37% +$250K 0.05% 168
2020
Q1
$587K Buy
7,703
+1,539
+25% +$131K 0.04% 210
2019
Q4
$546K Sell
6,164
-5,011
-45% -$416K 0.03% 235
2019
Q3
$846K Buy
11,175
+51
+0.5% +$3.5K 0.05% 174
2019
Q2
$809K Buy
11,124
+40
+0.4% +$3.14K 0.05% 182
2019
Q1
$893K Sell
11,084
-51
-0.5% -$4.17K 0.05% 172
2018
Q4
$1.03M Buy
11,135
+296
+3% +$26K 0.06% 179
2018
Q3
$1.02M Buy
10,839
+689
+7% +$65.3K 0.06% 169
2018
Q2
$940K Buy
10,150
+675
+7% +$65.9K 0.06% 172
2018
Q1
$897K Sell
9,475
-2,816
-23% -$309K 0.05% 169
2017
Q4
$1.19M Sell
12,291
-416
-3% -$39.2K 0.06% 159
2017
Q3
$1.13M Sell
12,707
-1,928
-13% -$147K 0.06% 143
2017
Q2
$1.06M Sell
14,635
-806
-5% -$54.2K 0.06% 153
2017
Q1
$1.01M Sell
15,441
-1,393
-8% -$87.6K 0.06% 143
2016
Q4
$1.05M Buy
16,834
+3,772
+29% +$230K 0.07% 135
2016
Q3
$824K Buy
13,062
+534
+4% +$34.6K 0.06% 149
2016
Q2
$776K Sell
12,528
-3,741
-23% -$228K 0.06% 155
2016
Q1
$929K Buy
16,269
+659
+4% +$36.7K 0.07% 127
2015
Q4
$925K Buy
15,610
+488
+3% +$28.1K 0.06% 134
2015
Q3
$823K Sell
15,122
-700
-4% -$45.6K 0.07% 123
2015
Q2
$1.06M Sell
15,822
-136
-0.9% -$8.88K 0.08% 113
2015
Q1
$934K Buy
15,958
+6,039
+61% +$365K 0.08% 108
2014
Q4
$649K Buy
9,919
+3,510
+55% +$221K 0.06% 126
2014
Q3
$370K Buy
6,409
+1,273
+25% +$70.7K 0.04% 159
2014
Q2
$290K Buy
5,136
+6
+0.1% +$315 0.03% 170
2014
Q1
$264K Sell
5,130
-413
-7% -$20.9K 0.03% 155
2013
Q4
$293K Sell
5,543
-8,810
-61% -$433K 0.04% 144
2013
Q3
$642K Buy
14,353
+9,355
+187% +$415K 0.1% 77
2013
Q2
$207K Buy
+4,998
New +$219K 0.04% 123

Other funds holding ABBV

First Foundation Advisors's ABBV Position: Q1 2026 in Review

First Foundation Advisors reduced its AbbVie (ABBV) stake by 3.2% in Q1 2026, selling an estimated $68.8K and leaving 9,520 shares worth $2.07M. The position accounts for 0.08% of the portfolio, ranked #140.

First Foundation Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.27M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • First Foundation Advisors held 9,520 shares of AbbVie worth $2.07M as of Q1 2026.
  • First Foundation Advisors sold 310 AbbVie shares in Q1 2026, an estimated $68.8K.
  • AbbVie made up 0.08% of First Foundation Advisors's portfolio in Q1 2026, its #140 holding.
  • First Foundation Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • First Foundation Advisors's AbbVie position peaked at $2.27M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on First Foundation Advisors's 13F filing for Q1 2026, filed 4 May 2026.